Health insurance catalog adjustment list public! 751 varieties passed the formal review.

On September 18, the State Administration of Health Insurance announced the List of Declared Drugs for the 2020 National Health Insurance Drug Catalog Adjustment through Formal Review, covering 751 varieties with a one-week publicity period.
7 conditions for the examination of the forms of Western and Chinese medicines in the catalogue: Condition 1: Drugs included in the New Coronavirus Pneumonia Diagnosis and Treatment Programme (Trial 7th Edition).
condition 2: Medicines included in the National Essential Medicines Directory (2018 edition).
Condition 3: To be included in the List of New Drugs In Clinically Urgent Need of Overseas Drugs (First Batch), List of New Drugs In Urgent Need of Overseas Medicines (Second Batch), List of First Batch of Encouraged Imitation Drugs, List of First Encouraging Research and Development of Declared Children's Drugs, or List of Third Batch of Children's Drugs For Encouraging Research and Development Declaration, and approved for listing by the State Drug Administration before August 17, 2020.
4: The second batch of state-organized drugs centralized procurement of the selected drugs.
5: From January 1, 2015 to August 17, 2020, a new generic drug was approved for sale by the State Drug Administration.
Condition 6: Between January 1, 2015 and August 17, 2020, according to the results of clinical trials, the State Drug Administration to supplement the application and obtain approval, adaptation, functional treatment and other significant changes in the drug.
conditions 7: By December 31, 2019, enter 5 (including) or more provincial-level the latest version of the basic medical insurance drug catalog of drugs.
, the main active ingredients are included in the "first batch of national key monitoring of rational drug use drug catalogue (chemical and biological products)" except.
conditions for the review of Western and traditional Chinese medicine forms in the catalogue are two: Condition 1: negotiated medicines that are within the validity period of the agreement and are subject to re-establishing the payment criteria in accordance with the agreement.
such as Acapo sugar, methyl sulfonate Oshitini, Ibdini, etc.
2: Negotiated drugs with significant changes in the treatment of adaptive disorders or functions within the validity period of the agreement and approved by the State Drug Administration.
such as Adamo monoanti, Olapali, hydrochloric acid and so on.
attached: